News
![Amgen's MariTide Weight Loss Potential: Stock Outlook: https://www.marketbeat.com/logos/articles/med_20240807084756_amgens-maritide-weight-loss-potential-stock-outloo.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMmJ3YkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--f8661f74d450e513993c46eccb7ecc5e4a54bad1/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20240807084756_amgens-maritide-weight-loss-potential-stock-outloo.png?locale=us)
Amgen's MariTide Weight Loss Potential: Stock Outlook
Amgen (NASDAQ: AMGN) is a biotechnology firm that has made its way into the weight loss treatment battle. The company’s shares have performed relatively well in 2024, providing a total return of
![Amgen's MariTide Weight Loss Potential: Stock Outlook: https://www.marketbeat.com/logos/articles/med_20240807084756_amgens-maritide-weight-loss-potential-stock-outloo.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMmJ3YkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--f8661f74d450e513993c46eccb7ecc5e4a54bad1/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20240807084756_amgens-maritide-weight-loss-potential-stock-outloo.png?locale=us)
Amgen's MariTide Weight Loss Potential: Stock Outlook
Amgen (NASDAQ: AMGN) is a biotechnology firm that has made its way into the weight loss treatment battle. The company’s shares have performed relatively well in 2024, providing a total return of
![Medical Technology Stock Benefits from Rising Acute Care Demand: https://www.marketbeat.com/logos/articles/med_20240804190513_chartg-syk.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeHJ3YkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--8f594e76b514dc585587c3092fa14586fececce4/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20240804190513_chartg-syk.jpg?locale=us)
Medical Technology Stock Benefits from Rising Acute Care Demand
Medical and surgical products manufacturer Stryker Co. (NYSE: SYK) is a beneficiary of the acute care boom occurring in the healthcare industry. Acute care is considered short-term intensive
![Humana Slides on Profitability Concerns Despite Q2 Earnings Beat: https://www.marketbeat.com/logos/articles/med_20240801073139_humana-slides-on-profitability-concerns-despite-q2.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNFBwYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--6cab1205557bb7b7a49eb3b07aef32f689be90f2/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20240801073139_humana-slides-on-profitability-concerns-despite-q2.jpg?locale=us)
Humana Slides on Profitability Concerns Despite Q2 Earnings Beat
Humana Inc. (NYSE: HUM) is a leading health insurer predominantly focused on Medicare Advantage plans, serving millions of individuals and families nationwide. The company's business model centers
![AbbVie Analysts Lead the Stock Higher as Humira Worries Recede: https://www.marketbeat.com/logos/articles/med_20240730104221_chart-abbv-7303034.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNHZtYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--35b89d873153e1f089b95f53e8fe2a230988c29a/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20240730104221_chart-abbv-7303034.png?locale=us)
AbbVie Analysts Lead the Stock Higher as Humira Worries Recede
AbbVie (NYSE: ABBV) was among the pharma companies worst positioned for a patent cliff that has come and gone. However, management's lean toward diversifying away from Humira and into a broader
![Pharma Stock Cuts Earnings Outlook: Still a Buying Opportunity: https://www.marketbeat.com/logos/articles/med_20240730092816_mrkchart730.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMkRtYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--dd4bd97e9b2e9c99997c053ac511b23dca201c57/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20240730092816_mrkchart730.png?locale=us)
Pharma Stock Cuts Earnings Outlook: Still a Buying Opportunity
Merck & Co. Inc. (NYSE: MRK) delivered a solid earnings report before the market opened on July 30, 2024. However, the stock was down over 4% in early trading after the company cut its full-year
![Top 2 Cheap Healthcare Stocks to Buy as Sector Outperforms: https://www.marketbeat.com/logos/articles/med_20240729132408_healthcare-sector-outperforms-2-cheap-healthcare-s.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBKy9sYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--3d9a042db8c33319140332cda195852f33ba54b8/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20240729132408_healthcare-sector-outperforms-2-cheap-healthcare-s.jpg?locale=us)
Top 2 Cheap Healthcare Stocks to Buy as Sector Outperforms
As the second half of the year has gotten underway, the healthcare sector, represented by the XLV ETF, has seen a notable resurgence. This sector, which had been underperforming since the
![Top 2 Cheap Healthcare Stocks to Buy as Sector Outperforms: https://www.marketbeat.com/logos/articles/med_20240729132408_healthcare-sector-outperforms-2-cheap-healthcare-s.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBKy9sYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--3d9a042db8c33319140332cda195852f33ba54b8/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20240729132408_healthcare-sector-outperforms-2-cheap-healthcare-s.jpg?locale=us)
Top 2 Cheap Healthcare Stocks to Buy as Sector Outperforms
As the second half of the year has gotten underway, the healthcare sector, represented by the XLV ETF, has seen a notable resurgence. This sector, which had been underperforming since the
![Viking Therapeutics: Pharma Stock Soars on Positive Earnings: https://www.marketbeat.com/logos/articles/med_20240725113846_viking-therapeutics-pharma-stock-soars-on-positive.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOW5oYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--700a93ac655e525cab3f2cdd260268378031f71c/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20240725113846_viking-therapeutics-pharma-stock-soars-on-positive.jpg?locale=us)
Viking Therapeutics: Pharma Stock Soars on Positive Earnings
Viking Therapeutics (NASDAQ: VKTX) is a clinical-stage biopharmaceutical company known for its focus on developing novel treatments for metabolic and endocrine disorders. Viking Therapeutics'
![Is This Telehealth Stock a Buy After the Recent Pullback?: https://www.marketbeat.com/logos/articles/med_20240719104001_is-this-telehealth-stock-a-buy-after-the-recent-pu.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBN3ZhYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--541dc31566e309ab26e834e21163c2ccb79ad4d4/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20240719104001_is-this-telehealth-stock-a-buy-after-the-recent-pu.jpg?locale=us)
Is This Telehealth Stock a Buy After the Recent Pullback?
Hims & Hers Health, Inc. (NYSE: HIMS) is a prominent player in the telehealth sector, which is part of the larger healthcare sector. The company has garnered significant attention from
![Is This Telehealth Stock a Buy After the Recent Pullback?: https://www.marketbeat.com/logos/articles/med_20240719104001_is-this-telehealth-stock-a-buy-after-the-recent-pu.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBN3ZhYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--541dc31566e309ab26e834e21163c2ccb79ad4d4/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20240719104001_is-this-telehealth-stock-a-buy-after-the-recent-pu.jpg?locale=us)
Is This Telehealth Stock a Buy After the Recent Pullback?
Hims & Hers Health, Inc. (NYSE: HIMS) is a prominent player in the telehealth sector, which is part of the larger healthcare sector. The company has garnered significant attention from
![Why This Leading Health Stock is a Buy No Matter the Market Move: https://www.marketbeat.com/logos/articles/med_20240718074551_chart-abt-7182024.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMURaYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--d3293d75b81fe2b099789a407dbbafa997e12be5/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20240718074551_chart-abt-7182024.png?locale=us)
Why This Leading Health Stock is a Buy No Matter the Market Move
Abbott Laboratories (NYSE: ABT) is a premier buy-and-hold stock because of its foresightful management, quality operation, portfolio, pipeline, cash flow, and capital return. It’s not always a
![Why This Healthcare Stock is a Strong Buy Despite Headwinds: https://www.marketbeat.com/logos/articles/med_20240716075118_chart-unh-7162024ver001.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBM25YYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--dec71f4e8f1aa03c6e044467887bd7e1caae5f40/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20240716075118_chart-unh-7162024ver001.png?locale=us)
Why This Healthcare Stock is a Strong Buy Despite Headwinds
UnitedHealth Group (NYSE: UNH) has headwinds, but its healthcare business and operational quality offset them, setting the stock to hit new all-time highs. The primary culprit is the recent
![Why This Healthcare Stock is a Strong Buy Despite Headwinds: https://www.marketbeat.com/logos/articles/med_20240716075118_chart-unh-7162024ver001.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBM25YYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--dec71f4e8f1aa03c6e044467887bd7e1caae5f40/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20240716075118_chart-unh-7162024ver001.png?locale=us)
Why This Healthcare Stock is a Strong Buy Despite Headwinds
UnitedHealth Group (NYSE: UNH) has headwinds, but its healthcare business and operational quality offset them, setting the stock to hit new all-time highs. The primary culprit is the recent
![Strategic Buy Lights Up This Biotech Stock: Time to Invest?: https://www.marketbeat.com/logos/articles/med_20240715092117_chartm-ilmn.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBK0xWYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--043b37e0d4b42e7edffe9bf194d0d64e594b7298/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20240715092117_chartm-ilmn.jpg?locale=us)
Strategic Buy Lights Up This Biotech Stock: Time to Invest?
Life sciences company Illumina Inc. (NASDAQ: ILMN) stock surged over 10% following its announcement of the acquisition of Fluent Biosciences. This comes after its divestiture and spin-off of
![Strategic Buy Lights Up This Biotech Stock: Time to Invest?: https://www.marketbeat.com/logos/articles/med_20240715092117_chartm-ilmn.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBK0xWYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--043b37e0d4b42e7edffe9bf194d0d64e594b7298/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20240715092117_chartm-ilmn.jpg?locale=us)
Strategic Buy Lights Up This Biotech Stock: Time to Invest?
Life sciences company Illumina Inc. (NASDAQ: ILMN) stock surged over 10% following its announcement of the acquisition of Fluent Biosciences. This comes after its divestiture and spin-off of
![Strategic Buy Lights Up This Biotech Stock: Time to Invest?: https://www.marketbeat.com/logos/articles/med_20240715092117_chartm-ilmn.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBK0xWYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--043b37e0d4b42e7edffe9bf194d0d64e594b7298/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20240715092117_chartm-ilmn.jpg?locale=us)
Strategic Buy Lights Up This Biotech Stock: Time to Invest?
Life sciences company Illumina Inc. (NASDAQ: ILMN) stock surged over 10% following its announcement of the acquisition of Fluent Biosciences. This comes after its divestiture and spin-off of
![CPI Data Sparks Rally in Biotech Stocks: https://www.marketbeat.com/logos/articles/med_20240715071929_cpi-data-sparks-rally-in-biotech-stocks.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeEhWYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--e72f3b13512241325fe9269e941b19b6d92017b2/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20240715071929_cpi-data-sparks-rally-in-biotech-stocks.jpg?locale=us)
CPI Data Sparks Rally in Biotech Stocks
The biotech sector has significantly lagged behind the overall market and its leading sector, technology, year-to-date. However, following the release of the CPI data on Thursday, the biotech
![CPI Data Sparks Rally in Biotech Stocks: https://www.marketbeat.com/logos/articles/med_20240715071929_cpi-data-sparks-rally-in-biotech-stocks.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeEhWYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--e72f3b13512241325fe9269e941b19b6d92017b2/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20240715071929_cpi-data-sparks-rally-in-biotech-stocks.jpg?locale=us)
CPI Data Sparks Rally in Biotech Stocks
The biotech sector has significantly lagged behind the overall market and its leading sector, technology, year-to-date. However, following the release of the CPI data on Thursday, the biotech
![CPI Data Sparks Rally in Biotech Stocks: https://www.marketbeat.com/logos/articles/med_20240715071929_cpi-data-sparks-rally-in-biotech-stocks.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeEhWYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--e72f3b13512241325fe9269e941b19b6d92017b2/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20240715071929_cpi-data-sparks-rally-in-biotech-stocks.jpg?locale=us)
CPI Data Sparks Rally in Biotech Stocks
The biotech sector has significantly lagged behind the overall market and its leading sector, technology, year-to-date. However, following the release of the CPI data on Thursday, the biotech
![Top 4 Must-Have Healthcare Stocks for Long-Term Growth: https://www.marketbeat.com/logos/articles/med_20240711100558_top-4-must-have-healthcare-stocks-for-long-term-gr.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBenpTYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--18c796118b42c488d1d1d9cbb3a7bd30f51bb02d/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20240711100558_top-4-must-have-healthcare-stocks-for-long-term-gr.jpg?locale=us)
Top 4 Must-Have Healthcare Stocks for Long-Term Growth
The healthcare industry represents a substantial and dynamic market sector, presenting many opportunities for investors seeking long-term growth and stability. Factors such as the aging
![Top 4 Must-Have Healthcare Stocks for Long-Term Growth: https://www.marketbeat.com/logos/articles/med_20240711100558_top-4-must-have-healthcare-stocks-for-long-term-gr.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBenpTYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--18c796118b42c488d1d1d9cbb3a7bd30f51bb02d/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20240711100558_top-4-must-have-healthcare-stocks-for-long-term-gr.jpg?locale=us)
Top 4 Must-Have Healthcare Stocks for Long-Term Growth
The healthcare industry represents a substantial and dynamic market sector, presenting many opportunities for investors seeking long-term growth and stability. Factors such as the aging
![3 Beaten Down Pharmaceuticals With Catalysts for Higher Prices: https://www.marketbeat.com/logos/articles/med_20240710114454_chart-crsp-7102024ver001.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOUhSYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--08a2149a6dcd0d6a884f68a6c8fde993a5634031/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20240710114454_chart-crsp-7102024ver001.png?locale=us)
3 Beaten Down Pharmaceuticals With Catalysts for Higher Prices
Trading volume spikes in beaten-down stocks often signal a bottom for prices investors can bank on. The problem is that beaten-down stocks are usually in that position for a good reason, so it
![3 Stock Giants Analysts Are Bullish On Despite Struggles: https://www.marketbeat.com/logos/articles/med_20240705084239_3-stock-giants-analysts-are-bullish-on-despite-str.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBM2pNYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--36338d066fa488a0781448b3590f0ae903c560ae/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20240705084239_3-stock-giants-analysts-are-bullish-on-despite-str.jpg?locale=us)
3 Stock Giants Analysts Are Bullish On Despite Struggles
Despite their recent struggles, these three industry giants hold the promise of significant upside. With favorable consensus price targets and ratings, attractive P/E valuations, solid earnings
![3 Stock Giants Analysts Are Bullish On Despite Struggles: https://www.marketbeat.com/logos/articles/med_20240705084239_3-stock-giants-analysts-are-bullish-on-despite-str.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBM2pNYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--36338d066fa488a0781448b3590f0ae903c560ae/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20240705084239_3-stock-giants-analysts-are-bullish-on-despite-str.jpg?locale=us)
3 Stock Giants Analysts Are Bullish On Despite Struggles
Despite their recent struggles, these three industry giants hold the promise of significant upside. With favorable consensus price targets and ratings, attractive P/E valuations, solid earnings